PP 91 THE APPLICATION OF SERUM BIOMARKERS TO DETECT PRE-MALIGNANT LESIONS IN GASTRIC CORPUS

Authors

  • H L Tan Unit of Gastroenterology and Hepatology, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  • C S Ngiu Unit of Gastroenterology and Hepatology, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  • N R Kosai Upper Gastrointestinal and Bariatric Surgery, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  • J Naidu Upper Gastrointestinal and Bariatric Surgery, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  • R Abdul Rani Faculty of Medicine, Universiti Teknologi Mara, Malaysia
  • M H Elias Department of Physiology, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  • N M Mokhtar Department of Physiology, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  • NA Hamid Faculty of Medicine and Health Science, University Sains Islam Malaysia
  • R A Raja Ali Unit of Gastroenterology and Hepatology, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

Abstract

INTRODUCTION

Gastric adenocarcinoma is often diagnosed at advanced stage, leading to cancer death. Corpus-predominant atrophic gastritis increases the risk of gastric cancer. We aim to investigate the utility of serum biomarkers to diagnose chronic atrophic gastritis (CAG) and intestinal metaplasia (IM) and determine the sensitivity and specificity of serum pepsinogen I (PGI), pepsinogen II (PGII), ratio of PGI to PGII (PG I/II) and gastrin-17 (G-17) in detecting these lesions.

MATERIALS AND METHODS

We performed a cross sectional observational study involving patients who underwent gastroscopy for dyspepsia in our unit. Endoscopic CAG is graded based on Kimura-Takemoto classification and gastric biopsies were analyzed using updated Sydney system. Serum PGI, PGII, G-17 and H. pylori antibody levels were measured by enzyme-linked immunosorbent assay. RESULTS A total of 72 patients with mean age of 56.2 years (±16.2) were recruited. The median level of PGI, PGII, PG I/II ratio and G-17 for all subjects were 129.9?g/L, 10.3?g/L, 14.7 and 4.4pmol/L respectively. Subjects with corpus CAG/IM had significantly lower PG I/II ratio (7.2, p< 0.001) compared to the control group (PG I/II=15.7). There was no significant difference in serum G-17 level between antral CAG/IM group and non-CAG group. Histological CAG and IM correlated well with serum PG I/II ratio (r = - 0.417, p< 0.001). The cut off value of PG I/II ratio of ? 10.0 exhibit high sensitivity (83.3%), specificity (77.9%) and area under the ROC curve (AUC) of 0.902 in detecting corpus CAG/IM. However, at PG I/II ratio of ? 3.0, the sensitivity was very low. Serum PG I, PGII and G-17 level have low sensitivity in detecting CAG/IM.

CONCLUSION

Serum PG I/II ratio could potentially be used as an outpatient and non-invasive method for detecting premalignant gastric lesions, in particular chronic atrophic gastritis and intestinal metaplasia in gastric corpus.

Metrics

Metrics Loading ...

Downloads

Download data is not yet available.

Downloads

Published

05-12-2016

Issue

Vol. 1 No. 2 (2016): Supplementary Issue

Section

Supplementary Issue